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Microarray-based comparative genomic hybridization (array CGH) is a newly emerged molecular cytogenetic technique for rapid
evaluation of the entire genome with sub-megabase resolution. It allows for the comprehensive investigation of thousands and
millions of genomic loci at once and therefore enables the eﬃcient detection of DNA copy number variations (a.k.a, cryptic
genomic imbalances). The development and the clinical application of array CGH have revolutionized the diagnostic process in
patients and has provided a clue to many unidentiﬁed or unexplained diseases which are suspected to have a genetic cause. In this
paper, we present three clinical cases in both prenatal and postnatal settings. Among all, array CGH played a major discovery role
to reveal the cryptic and/or complex nature of chromosome arrangements. By identifying the genetic causes responsible for the
clinical observation in patients, array CGH has provided accurate diagnosis and appropriate clinical management in a timely and
eﬃcient manner.
1.Introduction
Genomic disorders, resulting from DNA rearrangements
involving region-speciﬁc repeat sequences, are caused by
abnormal dosage of one or more genes located within
the rearranged genomic fragments. Cytogenetic analysis
has been a useful diagnostic tool for this disease cate-
gory especially in idiopathic developmental delay/mental
retardation, multiple congenital anomalies, dysmorphism,
and pregnancy at risk for chromosomal abnormalities.
However, the limitation of band resolution in the conven-
tional cytogenetic methodology karyotype (5–10Mb) has
prompted the development of technologies which can iden-
tify previously unrecognized chromosomal anomalies. Since
Solinas-Toldo et al. published the ﬁrst article on array-
based comparative genome hybridization (array CGH) in
1997 [1], this technique has become one of the fastest
growing ones due to its ability to screen a sample for
thousands to millions of diﬀerent loci at once. The array
CGH platforms used for clinical diagnosis are able to detect
nonmosaic and mosaic aneuploidies, subtelomeric imbal-
ances, known microdeletion/microduplication syndromes,
and other unique unbalanced chromosomal rearrangements
[2–4]. The detection rate has been improved to 10–16%
in patients with a normal karyotype [5, 6]. In addition,
array CGH is able to uncover numerous copy number
variations (CNVs) of not-yet-known clinical signiﬁcance
scattered throughout the human genome.
Inpediatric patientswithidiopathic developmentaldelay
and dysmorphic features, it is diﬃcult to come up with a
speciﬁc diagnosis due to the lack of cardinal features of a
syndrome. Similarly, in the prenatal setting when congenital
anomaliesareseenwhichdonotsuggestaspeciﬁcsyndrome,
it is especially diﬃcult to make the diagnosis within a
limited time frame so that appropriate management can
be performed. In these cases, the use of array CGH has
demonstrated great advantages to both patients and physi-
cians. First of all, the multiplex format of array enables the
simultaneous screening of hundreds of well-characterized
disease loci and the subtelomeric regions, leading to the2 Genetics Research International
shortened diagnostic process and reduced cost compared to
ordering sequential tests for each individual locus. Second,
arrayCGHis adiscovery-basedapproach.WhenaCNV with
unknown clinical signiﬁcance is identiﬁed, the genes located
within it become the potential candidates, which facilitate
further studies leading to disease gene discovery. Besides,
identifying novel CNVs may also help to characterize a
new genetic disorder. Third, the technical developments
from arrays based on BAC (bacteria artiﬁcial chromosome)
to oligonucleotide probes and the much improved array
resolution enable the potential to better deﬁne the boundary
of genomic gains and losses [7]. This is critical when an
annotated gene is located near the boundary. The accurate
deﬁnition of the genetic content within the duplicated
or deleted region is essential for the appropriate clinical
management of the patients and for the characterization of
involved genes [8].
We have chosen to focus on patients in whom the com-
plete cytogenetic abnormalities were principally discovered
by array CGH, rather than by conventional karyotyping or
ﬂuorescence insitu hybridization. By presenting the three
cases here, we would like to emphasize the power of array
CGH in identifying the genetic causes responsible for the
clinical presentations in the patients so that accurate diag-
nosis, prognosis, and clinical management can be provided
and achieved.
2.MaterialsandMethods
2.1. Patients. The patients and their families were recruited
through the Genetics Clinic at the Alberta Children’s Hos-
pital. Informed consents were obtained from the patients or
their parents.
2.2. Array CGH. Genomic DNA was extracted from the
whole blood of patients using Gentra Puregene Cell Kit
(Qiagen)accordingtothemanufacturer’sprotocol.Genomic
DNA from each patient was labeled with red ﬂuorescent
dye cyanine-5 (Cy-5) and hybridized with same-sex normal
reference DNA (Promega) labeled with green ﬂuorescent dye
Cy-3. Array CGH was performed using two platforms. The
ﬁrst platform, CytoChip ISCA 8 × 60K v2.0 Oligonusleotide
array (BlueGnome), consist of 60,000 oligonusleotides and
evaluates the whole genome with an eﬀective backbone
resolution of 170Kb. 137OMIM genes are represented with
average oligonucleotide spacing of 3.5Kb and at centromeres
and subtelomeres of 4.5Kb. The second platform, Cyto-
surs Syndrome Plus V2 2 × 105K Oligonucleotide array
(OGT),consistsof105,000oligonucleotideswithabackbone
resolution of 40Kb. 410 genes in disease associated areas are
targeted with oligonucleotide distributing every 3Kb. Sub-
telomeric regions are represented with an average resolution
of 40Kb.
Hybridization of highly repetitive sequences was sup-
pressed by addition of unlabeled Cot-1 DNA in the reac-
tion. Depending on the array platform used, the relative
hybridization signal intensity of the patient and control
was normalized using either BlueFuse Multi software v2.2
(CytoChip v2 algorithm) or Feature Extraction v10.7.3.1
(Agilent Technologies) and Cytosur 2.5.3 (OGT). The value
ofeachprobewascalculatedbythelog2oftheCy5/Cy3ratios
and plotted along each chromosome at the corresponding
locus. Genomic gains and losses were called by the software
when the average value of at least three consecutive oligo
probes is over +0.35 or below −0.4, respectively. Called
imbalances were further aligned with the in-house database
and the Database of Genomic Variants (DGV, NCBI 36/HG
18) to exclude benign copy number variations (CNVs).
Finally, the imbalances were examined in the USCS Genome
Browser (NCBI 36/HG 18) to determine whether they are
causative for the patient’s clinical presentation.
2.3. FISH Validation. The copy number variations identiﬁed
by a CGH, which we considered for further validation, were
analyzed using ﬂuorescence in situ hybridization (FISH)
analysis. FISH probes were either chosen from the eFISH
(build 36) and ordered from the Toronto Centre for Applied
Genomics or purchased commercially. FISH was performed
on metaphase chromosomes or interphase nuclei using
the standard FISH clinical protocol preestablished in the
Cytogenetic Laboratory in the Alberta Children’s Hospital.
Parental blood samples were examined to determine the
inheritance pattern of the variations.
3. Results and Discussion
3.1. Case No. 1. The couple came to our attention due to
the positive ﬁrst trimester screen. The woman is a healthy
25-year-old, G1P0. The ﬁrst trimester nuchal translucency
screen at 13 weeks was positive, and the couple decided to
proceed with chorionic villus sampling. To rule out common
chromosomal aneuploidies, ﬂuorescence in situ hybridiza-
tion (FISH) studies were performed using speciﬁc probes
targeting chromosome 13, 18, 21, X, and Y (AneuVysion
kit, Abbott Molecular Inc.), and the results were normal.
The followup G-banded chromosome study revealed a
reciprocal translocation involving the short arm of one
chromosome 11 and the short arm of one chromosome 12
– 46,XY,t(11;12)(p14;p13.2) (Figure 1(a)), which appeared
to be balanced. To determine whether this translocation
was familial, chromosome studies were performed on both
parents and the results were normal. Subsequent prenatal
ultrasounds showed signs of a signiﬁcant cardiac defect as
well as mild bilateral dilatation of the renal pelvis. Followup
fetal echocardiogram conﬁrmed the complex congenital
heart defect—left ventricular hypoplasia, ventricular septal
defect, and mild tricuspid insuﬃciency. Given the presence
of the de novo reciprocal translocation, it was suspected
that a cryptic imbalance may be present. Array CGH study
was therefore performed using the CytoChip ISCA 8 ×
60K v2.0 Oligonucleotide array platform (BlueGnome) and
showed that there is signiﬁcant copy number loss (5.48Mb
in size) on the long arm of chromosome 16 (q23.2-q24.1)
from nucleotide 79,945,820 to 85,430,304 (NCBI 36/HG
18) (Figure 1(b)). This deletion was conﬁrmed by FISH
studies using a BAC probe RP11-625B13 mapped to 16q23.3Genetics Research International 3
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Figure 1: Apparently balanced translocation is accompanied by a cryptic genomic deletion (a) Conventional karyotyping revealed a
reciprocal translocation involving the short arm of one chromosome 11 (11p14) and the short arm of one chromosome 12 (12p13.2), which
appears to be balanced. Chromosomes 16 appear normal. (b) Array CGH study detected a signiﬁcant copy number loss on chromosome 16
(q23.2-q24.1)(c)ThisdeletionwasconﬁrmedbyFISHstudiesusingaBACprobeRP11-625B13(red)mappedto16q23.3andacontrolprobe
RP11-6C20 (green) mapped to 16p13.3. (d) Genes located within the deleted region 16q23.2-q24.1 (nucleotide 79,945,820 to 85,430,304,
NCBI 36/HG 18) as shown by the UCSC genome browser. These include FOX family cluster FOXF1, FOXC2, and FOXL1.
(Figure 1(c)) and was not related to the translocation
breakpoints. FISH analysis was also performed on parental
blood samples which showed a normal result. Of note,
this large deletion on chromosome 16 is not detectable on
karyotype (Figure 1(a)).
The Database of Genomic Variants (DGV, NCBI 36/HG
18) is a useful tool to exclude benign CNVs. DGV revealed
that there are no reported benign CNVs encompassing this
deleted region, suggesting that it is not likely to be a benign
change. This de novo deletion encompasses multiple genes
including FOXF1, and two other related genes FOXC2 and
FOXL1 (Figure 1(d)). Deletion in FOXF1 is associated with
a lethal condition named alveolar capillary dysplasia with
misalignment of pulmonary veins (ACD/MPV, OMIM no.4 Genetics Research International
265380). Alveolar capillary dysplasia is characterized by
abnormal development of the capillary vasculature around
the alveoli leading to persistent pulmonary hypertension in
the early postnatal period [9]. Aﬀected infants are usually
born without any prior suspicion of lung malformation.
However, most babies deteriorate rapidly, and many die
of respiratory failure within the newborn period even
with signiﬁcant respiratory support [10]. Other features of
ACD/MPV include abnormal development of the cardio-
vascular,gastrointestinal,genitourinary,andmusculoskeletal
systems [11] .Ar e c e n ta r r a yC G Hs t u d yd e m o n s t r a t e dt h a t
alveolar capillary dysplasia is caused by the genomic deletion
of the FOX gene cluster [12]. It also suggests that the
cardiovascular malformation in this disorder is caused by the
haploinsuﬃciency for the neighboring FOXC2 and FOXL1
genes,asapatientwithadownstreamdeletionencompassing
just FOXC2 and FOXL1 exhibited cardiac defects without
any respiratory complications [12]. Therefore, this deletion
is considered pathogenic and would explain the fetal cardiac
anomalies seen on prenatal ultrasounds and fetal echocar-
diogram. The prognosis for this pregnancy is extremely poor
with the presence of the lethal condition ACD in addition
to the fetal cardiac anomalies. The previousy identiﬁed
reciprocal translocation t(11;12) and this large deletion are
most likely de novo events which occurred together within a
singlegermcell.Therefore,therecurrenceriskwillbelowfor
future pregnancies.
The majority of apparently balanced structural rear-
rangements are not associated with an abnormal pheno-
type. After the identiﬁcation of such rearrangements, it is
important to test the parents and determine whether it is
inherited or de novo. Inherited rearrangements have reduced
clinical concerns and are likely to be benign. However, de
novo apparently balanced rearrangements predispose to a
higherriskofacrypticgenomicimbalanceatthebreakpoints
or somewhere else, which may be causative for the clinical
phenotypes in the patients. Therefore, prenatal array CGH
should be recommended in such circumstances for better
clinical management.
3.2. Case No. 2. A 2-year boy was referred to the genetics
clinic for assessment of his recurrent thrombocytopenia,
short stature, and dysmorphic features. He was found to
have isolated thrombocytopenia during acute illnesses which
would resolve spontaneously with resolution of the inter-
current illness. Platelet count was below normal when well.
Hematologic investigations included a normal peripheral
blood smear, bone marrow aspirate and biopsy, and a
normal immune workup. His past medical history was
signiﬁcant for vesicoureteral reﬂux, hypospadias, bilateral
cryptorchidism, laryngomalacia, eczema, and constipation.
H eh a sm i l dﬁ n em o t o ra n ds p e e c hd e l a y sa sw e l la s
behavioural issues including poor socialization, aggressive
behaviour,anddecreasedattention.Onphysicalexamination
at 6 years of age his growth parameters were all below the
3rd percentile. He had coarse hair, hypertelorism, epicanthal
folds, short palpebral ﬁssures, a depressed nasal root with
a bulbous nasal tip, small teeth, low-set ears which were
posteriorly angulated as well as short 5th ﬁngers bilaterally
with clinodactyly of the 5th digit on the left hand. Review
of the family history revealed a younger brother who was
small for age but was proportionate. He was nondysmorphic
and had no other clinical concerns. Considering that he has
a normal karyotype and his parents are small in stature,
no further cytogenetic investigations (e.g., array CGH) were
performed.
Cytogenetic investigations in the patient showed a
chromosome abnormality with additional satellites on the
distal long arm of one chromosome 21 (46,XY,21qs), which
was conﬁrmed by FISH studies using an Acro-p probe
(AbbottMolecularInc.)(Figure 2(a)).Todetermine whether
this abnormality was familial, chromosome studies were
performed on both parents, and the results were normal.
Further FISH studies demonstrated a deletion of the 21q
subtelomere region (Figure 2(b)) with a diminished signal
for the RUNX1 locus (Figure 2(c)), suggesting that one of
the deletion breakpoints is located within the RUNX1 locus.
Due to the clinical signiﬁcance of haploinsuﬃciency for
the RUNX1 gene (as discussed below), further investigation
was undertaken to determine if the gene was completely
deleted. Surprisingly, array CGH analysis using the Cytosure
S y n d r o m eP l u sV 22× 105k Oligonucleotide array platform
(OGT) not only conﬁrmed the complete deletion of the
RUNX1 gene but it also revealed a complex chromosomal
rearrangement of chromosome 21 with interspersed dupli-
cations (×3) and deletions (×2) (Figure 2(d)).
The ﬁrst and most proximal copy number variation
(CNV) is a gain which encompasses a region of 1.1Mb from
nucleotide 23,449,744 to 24,557,710. DGV revealed there are
noreportedbenignCNVsfullyencompassingthisduplicated
region.However,therearenoknowngeneswithinthisregion
(by UCSC genome browser), suggesting that this duplicated
region is of no clinical signiﬁcance. The second CNV is a loss
which encompasses 1.81Mb from nucleotide 34,965,815 to
36,781,907 and includes the gene RUNX1 (Figure 2(e)). No
reported benign CNVs have been found encompassing this
loss (by DGV). Besides RUNX1 which will be discussed later,
there is another disease-associated OMIM gene CLDN14,
which is associated with a type of autosomal recessive
deafness. Since there is no concerns about the patient’s
hearing,haploinsuﬃciencyofCLDN14hasunknownclinical
signiﬁcance. The third CNV is a gain encompassing 0.42Mb
from nucleotide 37,847,805 to 38,276,148. There is no
reported benign CNVs fully encompassing this gain (by
DGV), and there is only one RefSeq gene KCNJ6 located
within it (by UCSC genome browser). Duplication of KCNJ6
is of unknown clinical signiﬁcance. The fourth CNV is
also a gain of 4.1Mb in size from nucleotide 40,917,977
to 45,022,823. Similar to the other two gains, there is no
reported benign CNVs fully encompassing this region (by
DGV). UCSC genome browser revealed several disease-
associated OMIM genes (TMPRSS3, CBS, CRYAA, CSTB,
AIRE,a n dPFKL). Mutations and/or deletions of these genes
are associated with various diseases. However, extra copies of
themareofunknownclinicalsigniﬁcance.Theﬁfthandmost
distal CNV is a terminal loss encompassing 1.82Mb fromGenetics Research International 5
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Figure 2: Complex rearrangement is revealed by array CGH. (a) FISH studies using acro-p probe targeting the short arms of all acrocentric
chromosomes (red) were used to investigate the additional satellite on the long arm of 21qs. Insert shows the G-banded 21 chromosome
with additional satellite on 21q (as indicated by ∗). (b) FISH studies using probes targeting 21q22 locus (encompassing RUNX1 gene, aqua)
and 21qter locus (yellow) were used to lineate the deleted chromosome 21. The del(21) lacks the yellow signal for the 21qter locus and has a
diminished signal for the 21q22 locus. The 4pter and 4qter probes were used because they are in the same cocktail with the 21q22 and 21qter
probes (Abbott Molecular Inc. ToTelVysion Vial no.4 probe set). (c) By using the RUNX1/RUNX1T1 (previously known as AML1/ETO) dual
color dual fusion translocation probe set (Abbott Molecular Inc), the FISH studies conﬁrmed the diminished signal for the RUNX1 locus.
(d) Array CGH study detected a complex rearrangement on the long arm of chromosome 21 with 3 copy number gains and 2 copy number
losses. (e) The second copy number variation (highlighted by the broken line in (d)) contains multiple annotated genes including RUNX1,
as shown by the UCSC genome browser.
nucleotide 45,096,184 to 46,920,235. DGV showed no re-
ported benign CNVs fullyencompassing this loss, and UCSC
genome browser revealed several disease-associated OMIM
genes (as follows). Biallelic loss-of-function mutations in
ITGB2, COL18A1, FTCD,a n dPCNT2 cause leukocyte
adhesion deﬁciency (OMIM no. 116920), Knobloch syn-
drome type I (OMIM no. 267750), formiminotransferase
deﬁciency (OMIM no. 229100), and type II icrocephalic
osteodysplastic primordial dwarﬁsm (OMIM no. 210720)
respectively. Whether haploinsuﬃciency of these genes is
associated with any clinical signiﬁcance remains unknown.
MutationsinCOL6A1andCOL6A2causetwoautosomaldo-
minant muscular diseases: Bethlem myopathy (OMIM no.
158810) and Ullrich congenital muscular dystrophy (OMIM
no. 254090). Haploinsuﬃciency of the two genes could
explainthe5thﬁngerclinodactylyandthedelaymotordevel-
opment observed in the patient [13, 14]. Of note, none of
the gains encompass the Down syndrome critical regions.
Besides, there is no probe between the fourth and the ﬁfth
CNVs and after the distal end of the ﬁfth CNV.
RUNX1, deleted in the second CNV, is a hematopoi-
etic transcription factor frequently involved in somatic or
acquired chromosome translocations associated with leu-
kemia [15, 16]. The constitutional mutations and deletions
of RUNX1 are known to be associated with familial platelet
disorder with propensity to acute myelogenous leukemia
(FPD/AML, OMIM no. 601399) [17, 18]. FPD/AML is an
autosomal dominant disorder which is characterized by the
prolongedbleedingtime,mild-to-moderatethrombocytope-
nia with normal platelet size and morphology, with or with-
out abnormal platelet aggregation in response to arachidonic
acid [19–21]. Predisposition to the development of myeloid
malignancies is another feature, with 20–50% progressing
into AML and myelodysplasia. A lower cancer risk has been
reported in individuals found to be haploinsuﬃcient for
RUNX1 while partial deletions or missense mutations have6 Genetics Research International
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Figure 3: Array CGH identiﬁed a genomic loss and gain responsible for the patient’s phenotype. (a) Patient’s photo at the age of nine. His
physical features demonstrate a relative macrocephaly with a prominent forehead, sparse hair and eyebrows, prominent ears which are low
set, and cup-shaped, deep set eyes with esotropia, astigmatism, and possible congenital anomaly of the left optic disc. (b) Array CGH study
detected a signiﬁcant copy number loss on chromosome 4 (q13.2-q21.1). (c) Array CGH study also identiﬁed a signiﬁcant copy number gain
on chromosome 6 (q24.3). (d) The deletion was conﬁrmed by FISH studies using a BAC probe RP11-165D10 (red) mapped to 4q13.2 and
a control probe RP11-483A2 (green) mapped to 4q25. (e) The gain was conﬁrmed by FISH studies using a BAC probe RP11-1077K2 (red)
mapped to 6q24.3 and a control probe RP11-346K8 (green) mapped to 6p21.33. Of note, D and E are the same metaphase with diﬀerent
probe sets to visualize both chromosomes 4 and 6. The extra red signal appears to locate on the derivative chromosome 4. (f) Genes located
within the deleted region 4q13.2-q21.1 (nucleotide 67,133,352 to 77,615,947, NCBI 36/HG 18) as shown by the UCSC genome browser. (g)
Genes located within the duplicated region 6q24.3 (nucleotide 146,155,718 to 148,055,364, NCBI 36/HG 18) as shown by the UCSC genome
browser.Genetics Research International 7
been associated with a higher risk for hematologic malig-
nancy. By using the array CGH analysis, we conﬁrmed that
the patient was haploinsuﬃcient for RUNX1 and thus has
a decreased risk for AML and myelodysplasia. Furthermore,
the complex rearrangement of chromosome 21 most likely
represents de novo events. Therefore, the recurrence risk will
be low for future pregnancies in this family.
3.3. Case No. 3. This patient is the ﬁrstborn child to a
healthy unrelated couple. At the time of birth the father
and the mother’s ages were 30 and 29, respectively. No
anomalies were seen on the prenatal ultrasound, and the
newborn was healthy. By nine months, the weight and length
were at the 3rd percentile, while the head circumference
remained at the 50th percentile. Developmental delay (delay
in sitting, standing, and walking) was evident in the ﬁrst
year. At 16 months, severe expressive language delay was
noted but receptive language was within normal limits. At
14 months, he had ﬁve seizures associated with fever and
some focal signs. The patient was ﬁrst seen at the genetics
clinic at 20 months. No precise diagnosis had been made
despitemanyinvestigations. Thekaryotypeshowedanormal
male chromosome complement. Subtelomere FISH studies
(TelVysion kit, Abbott Molecular Inc.) also showed a normal
result. Other studies included UPD7, multiple biochemical
tests, CT, brain MRI, skeletal survey, and thyroid studies
which were all normal. At seven years nine months, the
patient’s height and weight were less then the 3rd percentile
and head circumference remained at the 50th percentile.
Nowattheageofnine,hespeaksintelligiblyandinsentences.
There are no behavior problems, no further seizures, and no
sleep problems. He remains small despite a good appetite.
His physical features demonstrate a relative macrocephaly
with a prominent forehead, sparse hair and eyebrows,
prominent ears which are low set, and cup-shaped, deep
set eyes with esotropia, astigmatism, and possible congenital
anomaly of the left optic disc (Figure 3(a)).
Once the technology was developed locally, array CGH
was performed on the peripheral blood of the patient using
the CytoChip ISCA 8 × 60K v2.0 Oligonucleotide array
platform (BlueGnome). The array analysis identiﬁed two
chromosomal abnormalities. The ﬁrst one is a copy number
loss of a 10.5Mb region on the long arm of chromosome
4 (q13.2-q21.1) from nucleotide 67,133,352 to 77,615,947
(Figure 3(b)). According to DGV, there are no reported ben-
ign CNVs fully encompassing this large deletion. The clinical
signiﬁcanceofthedeletionwillbediscussedlater.Thesecond
one is copy number gain of a 1.9Mb region on the long arm
of chromosome 6 (q24.3) from nucleotide 146,155,718 to
148,055,364 (NCBI 36/HG 18) (Figure 3(c)). DGV showed
no reported benign CNVs fully encompassing this duplica-
tion, and UCSC genome browser revealed that there are no
disease-associated OMIM genes within this region. In order
to validate the array result, FISH studies were performed
using a BAC probe RP11-135D10 mapping to the deleted
region 4q13.2, a BAC probe RP11-1077K2 mapping to the
duplicatedregion6q24.3,twocontrolprobeson4q25(RP11-
483A2) and on 6p21.33 (RP11-346K8) (RPC1-11 Human
BAC library–CIHR Genome Resource Facility). Metaphase
FISHconﬁrmedthedeletion at4q13.2 and theduplication at
6q24.3. Interestingly, the third copy of 6q24.3 was located at
4q13 (Figures 3(d) and 3(e)). To further investigate whether
this complex rearrangement is de novo or inherited, FISH
studies were performed on the parental samples using the
above 4 probes. The mother’s result revealed a normal
hybridization pattern with all probes hybridizing at the
expected locations and with the expected copy number. The
father’sresult,however,identiﬁedanabnormalhybridization
pattern involving one chromosome 4 and one chromosome
6. The segment 4q13.2-q21.1 and the segment 6q24.3 are
involved in a reciprocal insertional translocation which
appears to be balanced (Figures 4(a) and 4(b)). Therefore,
the patient’s father has a four-break balanced complex
rearrangement t(4;6)(q13.2q21.1;q24.3q24.3) which is not
evident on the routine G-banded chromosomes. During the
paternal meiosis, the der(4)t(4;6) and normal chromosome
6 segregated together and resulted in the chromosomal
imbalances in this patient.
The patient’s clinical presentation is most likely due to
the deletion and duplication of many genes involved in
the imbalanced regions (Figures 3(f) and 3(g)). However,
thereisalimitedgenotype-phenotypecorrelationintermsof
each gene involved. The 10.5Mb deletion on chromosome 4
contains8disease-associatedOMIMgenes(GNRHR,MUC7,
ENAM, SLC4A4, GC, ALB, AFP,a n dSCARB2). Among
these, ENAM mutations are associated with amelogenesis
imperfecta, type 1B (OMIM no. 104500) which is an
inherited defect of dental enamel formation with autosomal
dominance as the likely mode of inheritance. However, this
patient has a full set of primary teeth with normal tooth
shape and enamel but delayed secondary teeth erupting.
Currently, it is unclear whether haploinsuﬃciency of ENAM
is responsible for the delay in secondary teeth erupting. The
1.9Mb duplication on chromosome 6 does not contain any
disease-associated OMIM genes (UCSC genome browser),
and its clinical signiﬁcance remains unknown.
ThroughcombiningarrayCGHandFISHtechniques,we
successfully identiﬁed the genomic imbalances responsible
for the patient’s clinical manifestation and further a familial
chromosomal rearrangement which changes the predicted
outcome and clinical management in this family. The
father now carries a signiﬁcant risk of having another ab-
normal liveborn with either der(4)t(4;6) as in the patient or
der(6)t(4;6) (Figure 4(c)). Therefore, prenatal diagnosis will
be oﬀered for any future pregnancies. The patient has two
siblings who are both normal. Cytogenetic testing will be
available to determine the carrier status when they become
adults.
4. Conclusions
ThewideapplicationofarrayCGHhasremarkablyimproved
the detection of DNA copy number variation and complex
chromosome rearrangement. It has revolutionized the diag-
nostic process of patients with global developmental delay,
dysmorphic features, multiple congenital anomalies, as well8 Genetics Research International
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Figure 4: FISH studies revealed a four-break balanced complex rearrangement in the patient’s father. (a) By using BAC probe RP11-165D10
(red) and control probe RP11-483A2 (green), FISH studies identiﬁed that the 4q13.2 segment has moved from derivative chromosome 4 to
derivative chromosome 6. (b) By using BAC probe RP11-1077K2 (red) and control probe RP11-346K8 (green), FISH studies identiﬁed that
the 6q24.3 segment has moved from derivative chromosome 6 to derivative chromosome 4. (c) A simpliﬁed diagram to show the increased
risk of having an unbalanced oﬀspring in this family. Green represents the 4q13.2-q21.1 segment and the red represents the 6q24.3 segments.
In the father, the green and red segment, switch locations leading to unbalanced oﬀspring with either 3 copies of the red segment and 1 copy
of the green segment (as in the patient) or 3 copies of the green segment and 1 copy of the red segment.
as complicated pregnancy at risk for chromosomal aberra-
tions. By identifying the genomic imbalances responsible for
the clinical presentation in patients, clinicians can provide
an accurate diagnosis, predict the potential risk in the future
andaltertheclinicalmanagementinthepatientsand/ortheir
families.
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